• Advancing Bioluminescent Assays with EZ Cap™ Firefly Lucifer

  2026-07-19

  Uncover how Firefly Luciferase mRNA with 5-moUTP modification elevates mRNA delivery and reporting, leveraging LNP innovations for robust, immune-silent gene expression studies. This article provides deep technical insight and unique comparative analysis.

• FPR2/ALX Stimulation Limits Neuroinflammation via Microglia

  2026-07-18

  The reference study demonstrates that stimulating FPR2/ALX with Quin-C1 in a mouse model of autoimmune astrocytopathy reduces neuroinflammation and demyelination by modulating microglia and natural killer (NK) cell activity. These findings clarify the underlying SYK-AKT pathway and highlight FPR2/ALX as a promising target for treating diseases such as neuromyelitis optica spectrum disorder (NMOSD).

• NMDA (N-Methyl-D-aspartic acid) in Excitotoxicity & Neurodeg

  2026-07-17

  NMDA (N-Methyl-D-aspartic acid) from APExBIO is a benchmark tool for modeling excitotoxicity and neurodegenerative mechanisms in vitro and in vivo. Its validated use in glaucoma models and oxidative stress assays enables reproducible insights into neuronal cell death and protection strategies.

• Palmitic acid (Hexadecanoic Acid): Technical Parameters & Us

  2026-07-17

  Palmitic acid (SKU N2456) addresses the need for a high-purity, well-characterized saturated long-chain fatty acid suitable for research on lipid metabolism, metabolic disorder pathways, and protein palmitoylation. It is not appropriate for workflows requiring aqueous solubility or long-term solution storage, and precise handling is essential to ensure reproducibility.

• HDAC Inhibitors Suppress NUT Function in NUT Carcinoma Cells

  2026-07-16

  Shiota et al. conducted a high-throughput chemical screen that revealed diverse histone deacetylase (HDAC) inhibitors as potent repressors of NUT-mediated transcriptional activity in NUT carcinoma. This work highlights the mechanistic role of HDAC inhibition in disrupting oncogenic chromatin megadomains, offering new insights into epigenetic vulnerabilities and treatment strategies for this aggressive cancer.

• YAP-TEAD–Super-Enhancer Regulation in Surface Ectoderm Fate

  2026-07-16

  Wang et al. reveal how the YAP-TEAD transcriptional complex orchestrates a super-enhancer (SE) network to drive early surface ectoderm commitment from pluripotent stem cells. Their integrative chromatin mapping and functional genomics uncover a new mechanistic axis for regulating epithelial lineage specification, informing future regenerative and stem cell-based strategies.

• ARCA Cy5 EGFP mRNA (5-moUTP): Optimizing mRNA Delivery Assay

  2026-07-15

  ARCA Cy5 EGFP mRNA (5-moUTP) empowers researchers with dual fluorescent tracking of mRNA localization and translation, streamlining delivery and immune evasion studies. Its 5-methoxyuridine modification and ARCA cap enable robust, quantifiable workflows for mRNA delivery system research and troubleshooting.

• Anagliptin (SK-0403) in Vascular and Diabetes Research Workf

  2026-07-15

  Anagliptin (SK-0403) empowers researchers to dissect DPP-4 inhibition and unique vasorelaxant mechanisms via Kv channels and SERCA pumps, offering precision for both metabolic and vascular studies. This guide delivers actionable protocols, troubleshooting advice, and insight into leveraging APExBIO’s Anagliptin for advanced experimental designs.

• Tacrine Hydrochloride Hydrate for Advanced Alzheimer’s Resea

  2026-07-14

  Tacrine hydrochloride hydrate (Tetrahydroaminacrine) is a benchmark tool for dissecting cholinergic pathways and neurodegeneration in Alzheimer’s disease models. This guide connects rigorous experimental protocols with troubleshooting insight, demonstrating how APExBIO’s high-purity formulation empowers reproducible, translational neuroscience.

• Deferasirox (A8639): Precision Iron Chelation for Cancer Res

  2026-07-14

  This article addresses real-world challenges in cell viability and ferroptosis research, demonstrating how Deferasirox (SKU A8639) delivers reproducible, data-driven solutions for iron chelation assays. Scenario-based Q&As guide scientists through protocol optimization, data interpretation, and vendor selection, highlighting APExBIO's product as a reliable standard.

• Primary Antibody Dilution Buffer: Precision in CNS Lymphoma

  2026-07-13

  Explore how the Primary Antibody Dilution Buffer enhances immunoassay specificity and sensitivity in challenging CNS lymphoma research. This article goes beyond standard protocols, offering scientific insights and practical guidance for advanced tissue analysis.

• FK866 (APO866): Lab-Proven Solutions for NAMPT Inhibition

  2026-07-13

  This article guides biomedical researchers through the practical challenges of NAMPT inhibition using FK866 (APO866), SKU A4381. Each scenario addresses a real laboratory pain point, offering evidence-based, workflow-driven answers. Protocol details and scientific references support reproducibility and reliability, positioning FK866 (APO866) as a trusted standard in cell viability and hematologic cancer research.

• Mavorixafor as a CXCR4 Antagonist in WHIM Syndrome: Phase 3

  2026-07-12

  The reference phase 3 trial demonstrates that mavorixafor, a selective oral CXCR4 antagonist, significantly increases neutrophil and lymphocyte counts and reduces infection rates in WHIM syndrome patients. This study marks a substantial advance in targeted therapy for this rare immunodeficiency, highlighting both clinical efficacy and manageable safety.

• 4-Methylumbelliferyl-β-D-Glucopyranoside in Lysosomal Enzyme

  2026-07-10

  4-Methylumbelliferyl-β-D-Glucopyranoside (4-MUG) is a fluorogenic substrate enabling sensitive, quantitative lysosomal enzyme activity assays. Its hydrolysis by β-glucosidase or β-glucocerebrosidase is central to glycosphingolipid metabolism research, including Gaucher disease models. The substrate’s robust fluorescence and solubility profile allow for versatile assay integration across biomedical research.

• Optimizing STAT3 Pathway Research with AZD1480 JAK2 Inhibito

  2026-07-09

  AZD1480 stands out as a highly selective and potent JAK2 inhibitor, uniquely suited for dissecting STAT3-driven tumor biology and overcoming immunotherapy resistance. This article details hands-on workflows, troubleshooting strategies, and insights from recent research to maximize experimental success in cancer signaling studies.

453 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page